Medicare AI Expansion: Who Wins the Digital Health Gold Rush?

The expansion of Medicare reimbursement for AI-driven cardiac diagnostics is not merely a policy adjustment. It is a seismic event reshaping the financial field of digital health. For CMS policy analysts, healthcare financial officers, and digital health investors, understanding the intricate dance between updated physician fee schedules and clinical adoption rates is paramount. This annual ranking digs into who stands to gain and who faces new challenges as Centers for Medicare & Medicaid Services (CMS) policy directly dictates market winners in the burgeoning field of healthcare AI.

The Reimbursement Catalyst: How CMS Funding Drives AI Adoption

The adage “follow the money” holds particularly true in healthcare, where reimbursement policy acts as the ultimate accelerant or decelerant for technological innovation. When CMS, the largest payer in the United States, opens its purse strings for a new technology, it signals a powerful validation that transcends mere clinical efficacy. It transforms a promising innovation into a financially viable, and therefore widely adoptable, solution. This massive shift in clinical adoption, triggered when CMS funds AI, is precisely what we are witnessing with advanced cardiac diagnostics. The Centers for Medicare & Medicaid Services (CMS) Medicare Physician Fee Schedule (MPFS) is the bedrock upon which much of this financial viability is built. For AI-powered diagnostics, securing appropriate Current Procedural Terminology (CPT) codes and favorable reimbursement rates within the MPFS is a critical milestone. It allows providers to integrate these tools into their workflows without incurring unrecoverable costs, thereby directly influencing the rate of clinical uptake. Plus, the New Technology Add-on Payment (NTAP) program, while primarily focused on inpatient settings, offers an additional layer of financial support for qualifying new technologies, bridging payment gaps and incentivizing early adoption for novel devices that demonstrate substantial clinical improvement.

Ranking the Financial Benefits: HeartFlow and Cleerly Lead the Charge

The latest CMS fee schedules reveal clear beneficiaries in the cardiac AI space, with companies like HeartFlow and Cleerly demonstrating how successful navigation of the reimbursement field translates into significant market advantage. These companies have not only secured regulatory clearances but have also established critical reimbursement pathways, positioning them as leaders in the economic and market analysis of AI-driven diagnostics.

HeartFlow: Paving the Way with CT-FFR Reimbursement

HeartFlow, with its AI-powered fractional flow reserve computed tomography (CT-FFR) analysis, has been a trailblazer in securing strong reimbursement. The company’s CT-FFR technology (CPT 75580) and its AI-enabled plaque quantification technology (CPT 75577, effective January 2026, replacing prior Category III codes) have garnered specific reimbursement codes, significantly easing its integration into clinical practice. HeartFlow’s ability to establish a patent thicket around CT-FFR has also provided a competitive moat, making it challenging for new entrants to replicate their market position without significant licensing costs or litigation risk. CMS Physician Fee Schedule final rule details on CT-FFR codes CMS has consistently recognized the value of CT-FFR, granting it favorable reimbursement. This has directly fueled adoption rates among cardiologists and hospitals seeking to non-invasively assess coronary artery disease. The financial incentive provided by CMS reimbursement transforms CT-FFR from an innovative but potentially costly diagnostic tool into a standard of care, driving both clinical volume and investment interest.

Cleerly: Expanding the Horizon for AI-Driven Atherosclerosis Detection

Cleerly represents another compelling case study in using reimbursement for market leadership. Their AI-driven analysis of coronary computed tomography angiography (CCTA) images quantifies and characterizes coronary plaque, moving beyond traditional stenosis assessment to provide a more complete picture of atherosclerosis. This approach aligns with a growing understanding of cardiovascular disease, where plaque burden and characteristics are critical prognostic indicators. Cleerly has successfully secured reimbursement pathways for its AI-powered CCTA analysis, allowing providers to bill for its advanced diagnostic insights. This includes Category I CPT code 75577 for AI-QCT advanced plaque analyses, effective January 2026, and Category I CPT code 75580 for non-invasive estimates of fractional flow reserve (FFR) from CCTA, effective January 2024. While their NTAP status requires careful review of the latest CMS publications, their strategic focus on demonstrating clinical utility and economic value has been key to their reimbursement success. NTAP program listings for recent AI technologies The ability to move beyond a simple “yes/no” answer on blockages to provide granular details on plaque composition and burden offers a powerful value proposition for both clinicians and payers. This detailed information can guide more precise treatment decisions, potentially leading to better patient outcomes and reduced downstream costs, a narrative that resonates strongly with CMS policy analysts.

How Reimbursement Policy Dictates Market Winners

The experiences of HeartFlow and Cleerly underscore a fundamental truth in healthcare: reimbursement policy is not merely an administrative detail. It is the primary determinant of market success for novel technologies. For digital health investors, understanding this dynamic is important for identifying viable investment opportunities. Companies that proactively engage with regulatory bodies like the FDA for 510(k) clearance or De Novo classification, and then carefully build a case for reimbursement with CMS, are the ones that will capture significant market share. The absence of clear reimbursement pathways, conversely, can relegate even clinically superior technologies to the status of a “zombie company”, a startup that secured initial funding and perhaps even FDA clearance, but struggles to achieve commercial scale due to lack of payer coverage. This phenomenon is particularly relevant for AI-native companies, whose core product and business model are intrinsically linked to the performance and utility of their algorithms. For healthcare financial officers, the implications are equally deep. The availability of specific CPT codes and favorable reimbursement rates directly impacts a hospital system’s ability to adopt and scale AI diagnostics. Without these financial mechanisms in place, even technologies with compelling clinical evidence may remain niche, limited to research institutions or cash-pay models. The ECRI AI healthcare hazard rankings, which often highlight the financial and operational risks associated with integrating new technologies, implicitly acknowledge the critical role of reimbursement in mitigating these hazards. ECRI hazard rankings for emerging health technologies The current field, with its focus on value-based care and outcomes, further amplifies the importance of reimbursement. AI diagnostics that can demonstrate improved patient outcomes, reduced costs, or enhanced efficiency are more likely to secure favorable coverage. This requires strong real-world evidence (RWE) to supplement traditional clinical trial data, building a complete narrative for both regulatory bodies and payers.

Methodology and Source Note

This analysis is grounded in a thorough review of publicly available information from the Centers for Medicare & Medicaid Services (CMS). Specifically, our insights are derived from the official CMS Medicare Physician Fee Schedule (MPFS) final rules and the New Technology Add-on Payment (NTAP) program listings, as published in the Federal Register. We carefully track updates to these publications to identify changes in reimbursement codes, rates, and eligibility criteria that directly impact the financial viability and clinical adoption of AI-driven diagnostic technologies. The information presented herein reflects the most current understanding of these policies, vital for CMS policy analysts, healthcare financial officers, and digital health investors working through this rapidly evolving sector.